Akademik Veri Yönetim Sistemi
Sülkü S. N., Aydin Son Y., Işil Ülman F. Y.
AB Destekli Diğer Projeler, 2022 - 2022
ERA-PER-MED
JOINT TRANSNATIONAL CALL FOR PROPOSALS (2022) FOR
“PREVENTION INPERSONALISED MEDICINE”
ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded
by the European Commission. To align national research strategies, promote excellence,
reinforce the competitiveness of European players in Personalised Medicine (PM), and
enhance the European collaboration with non-EU countries, 32 funding organisations have
agreed to launch the fifth joint transnational call for collaborative innovative research projects
in Personalised Medicine (PM). This represents the fourth call not co-funded by the European
Commission. The funding organisations participating in this call particularly wish to promote
innovative interdisciplinary collaboration and to encourage translational research proposals.
The call is planned to be launched on December 1
st
, 2021, with a submission deadline for preproposals on February 17, 2022. It is expected, that consortia invited for the full-proposal
stage, will need to submit their proposals on June 14th
, 2022.
The available budget for this call is 27 Mio€ (approx.).
An open information day introducing the joint transnational call 2022 to the research
community will be organised by ERA PerMed on December 9th, 2021. More information will
follow soon.
AIMS OF THE CALL
Through its fifth transnational call, ERA PerMed aims to foster research on prevention in
personalised medicine. The overarching goal of the call is the development of tailor-made
strategies for prevention of disease and disease progression, at three different levels:
i. preventive measures decreasing the rate of incidence (primary prevention),
ii. early detection to increase the efficacy of a preventive therapy, even before symptoms
are developed (secondary prevention), and iii. interventions preventing disease recurrence or improving patients’ care and quality of
life (tertiary prevention).
Research on prevention from over-treatment or over medicalisation in primary, secondary and
tertiary personalised preventive approaches is optional and could be part of research
proposals, if applicable.
The clinical relevance of the proposed PM approach needs to be convincingly demonstrated.
The overall objectives of the ERA PerMed call are (i) to support translational research projects
in the field of Personalised Medicine; (ii) to encourage and enable interdisciplinary
collaborations towards implementation of PM, in combining pre-clinical or clinical research
with bio-informatics components as well as ELSA research or implementation research,
including health economics; (iii) to encourage collaboration between academia (research
teams from universities, higher education institutions, public research institutions, research
centres), clinical/public health research (research teams from hospital/ public health,
healthcare settings and other healthcare organisations), private partners e.g. SMEs(small and
medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient
organisations.